Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Get Alerts MIST Hot Sheet
Join SI Premium – FREE
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 AM ET. The conference will be held in a virtual meeting format.
A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.
Contact
David PittsArgot Partners212-600-1902[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-jefferies-virtual-london-healthcare-conference-301170433.html
SOURCE Milestone Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
- World's First Autonomous Humanoid Tennis Match: GALBOT Robots Complete 100+ Consecutive Rallies
- TTW Announces the Top 50 Travel Solution Cards in the World for 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share